Abstract
Antibody-based therapeutics have emerged as novel class of biopharmaceuticals over the last couple of decades with the advancements made in production and downstream processing technologies. The structural diversity of therapeutic antibodies has also evolved with the development of bispecific (and multispecific) antibodies and antibody-drug conjugates. With increased structural complexities and multi-modularity, there is a need to demonstrate that the entire structure is stable in vivo and arriving at its target site in an intact form. Proving that antibodies reach their target site unscathed is a challenging but essential step for showing effective delivery as well as showing whether failure in efficacy (if any) was related to its in vivo instability. This chapter describes a method for highly specific immuno-isolation followed by intact mass spectrometry of human Fc-containing antibody from serum of rats dosed with the antibody. The method provides an opportunity for evaluating antibody stability in the physiological environment by providing accurate validation of its molecular mass in vivo, as well as the potential to identify breakdown products.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ecker DM, Jones SD, Levine HL (2015) The therapeutic monoclonal antibody market. MAbs 7:9–14
Schiel JE, Mire-Sluis A, Davis D (2014) Monoclonal antibody therapeutics: the need for biopharmaceutical reference materials. In: Schiel JE, Davis DL, Borisov OV (eds) State-of-the-art and emerging technologies for therapeutic monoclonal antibody characterization volume 1. Monoclonal antibody therapeutics: structure, function, and regulatory space. Am Chem Soc, Washington, DC, pp 1–34
Drugs@FDA: FDA approved drug products. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Accessed 10 Jul 2018
McCombs JR, Owen SC (2015) Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry. AAPS J 17:339–351
Spiess C, Merchant M, Huang A, Zheng Z, Yang N-Y, Peng J, Ellerman D, Shatz W, Reilly D, Yansura DG, Scheer JM (2013) Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat Biotechnol 31:753–758
Stanimirovic D, Kemmerich K, Haqqani AS, Farrington GK (2014) Engineering and pharmacology of blood-brain barrier-permeable bispecific antibodies. Adv Pharmacol 71:301–335
Wickramasinghe D (2013) Tumor and T cell engagement by BiTE. Discov Med 16:149–152
Chames P, Baty D (2009) Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs 1:539–547
Beck A, Wurch T, Bailly C, Corvaia N (2010) Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 10:345–352
Beck A, Goetsch L, Dumontet C, Corvaïa N (2017) Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov 16:315–337
Razinkov VI, Treuheit MJ, Becker GW (2015) Accelerated formulation development of monoclonal antibodies (mAbs) and mAb-based modalities. J Biomol Screen 20:468–483
Ross PL, Wolfe JL (2016) Physical and chemical stability of antibody drug conjugates: current status. J Pharm Sci 105:391–397
Correia IR (2010) Stability of IgG isotypes in serum. MAbs 2:221–232
Zhang H, Cui W, Gross ML (2014) Mass spectrometry for the biophysical characterization of therapeutic monoclonal antibodies. FEBS Lett 588:308–317
Xu K, Liu L, Saad OM, Baudys J, Williams L, Leipold D, Shen B, Raab H, Junutula JR, Kim A, Kaur S (2011) Characterization of intact antibody–drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography–mass spectrometry. Anal Biochem 412:56–66
Diamantis N, Banerji U (2016) Antibody-drug conjugates—an emerging class of cancer treatment. Br J Cancer 114:362–367
Sauerborn M, van Dongen W (2014) Practical considerations for the pharmacokinetic and immunogenic assessment of antibody–drug conjugates. BioDrugs 28:383–391
Ishihara T, Nakajima N, Kadoya T (2010) Evaluation of new affinity chromatography resins for polyclonal, oligoclonal and monoclonal antibody pharmaceuticals. J Chromatogr B 878:2141–2144
Tanha J, Muruganandam A, Stanimirovic D (2003) Phage display technology for identifying specific antigens on brain endothelial cells. Methods Mol Med 89:435–449
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Delaney, C.E., Kelly, J.F., Ding, W., Haqqani, A.S. (2019). Intact Mass Spectrometry Analysis of Immuno-Isolated Human Therapeutic Antibodies from Serum. In: Fulton, K., Twine, S. (eds) Immunoproteomics. Methods in Molecular Biology, vol 2024. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9597-4_9
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9597-4_9
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-9596-7
Online ISBN: 978-1-4939-9597-4
eBook Packages: Springer Protocols